Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

University of California, Los Angeles Wins the Humana-Mays Health Care Analytics Case Competition
University of California, Los Angeles Wins the Humana-Mays Health Care Analytics Case Competition


The student team of Ozguk Cetinok, Leah Kelly, and Erica Millwater from the University of California, Los Angeles (UCLA) has won the $30,000 First Place prize in the Humana-Mays Health Care

Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals
Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals


The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly

Humana Pharmacy Wins Surescripts 2019 White Coat Award™ For Prescription Accuracy
Humana Pharmacy Wins Surescripts 2019 White Coat Award™ For Prescription Accuracy


Humana Pharmacy, the mail-delivery pharmacy service of Humana Inc. (NYSE: HUM), has won the prestigious 2019 Surescripts White Coat Award, an honor that celebrates healthcare industry leaders

Humana Is No. 1 in Customer Service Among Health Insurance Companies, as Ranked by Newsweek
Humana Is No. 1 in Customer Service Among Health Insurance Companies, as Ranked by Newsweek


For the second year in a row, Humana Inc. (NYSE: HUM) rose to the top as No. 1 in service in its industry, according to Newsweek’s 2020 list of America’s Best Customer Service.



“We’re proud to

Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination
Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination


Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be

Humana again gets Gold award in American Heart Association’s Workplace Health Achievement Index
Humana again gets Gold award in American Heart Association’s Workplace Health Achievement Index


For the third year in a row, Humana Inc. (NYSE: HUM) has achieved top Gold-level recognition in the American Heart Association’s Workplace Health Achievement Index, a science-based assessment that

Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting
Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting


Pfizer Inc. (NYSE: PFE) announced today that positive results from a Phase 3 investigational study of tofacitinib in children and adolescents aged two to less than 18 with juvenile idiopathic

Waters Advanced Polymer Chromatography System Now First Fully Solvent-Compatible UPLC System for Greater Flexibility and Speed
Waters Advanced Polymer Chromatography System Now First Fully Solvent-Compatible UPLC System for Greater Flexibility and Speed


Waters Corporation (NYSE:WAT) announced today that its ACQUITY™ Advanced Polymer Chromatography™ (APC™) System is the first fully solvent-compatible UltraPerformance Liquid Chromatography

Agilent Named One of Top 10 Best Workplaces in Singapore
Agilent Named One of Top 10 Best Workplaces in Singapore


Agilent Technologies, Inc. (NYSE: A) today announced it has been named among the top 10 Best Workplaces™ in Singapore for 2019 by the Great Place to Work® (GPTW) Institute. Agilent was selected as

CORRECTING and REPLACING Agilent Technologies to Host Conference Call to Review Fourth Quarter Fiscal Year 2019 Financial Results; Announces Schedule for Upcoming Webcasts
CORRECTING and REPLACING Agilent Technologies to Host Conference Call to Review Fourth Quarter Fiscal Year 2019 Financial Results; Announces Schedule for Upcoming Webcasts
In release dated November 4, 2019, the Piper Jaffray Conference webcast date should read: December 4 (instead of December 3), and the Evercore webcast date should read: December 5 (instead of
Biogen: Neue Hoffnung auf ein Alzheimer-Medikament treibt Aktie an!
Biogen: Neue Hoffnung auf ein Alzheimer-Medikament treibt Aktie an!

Einer der größten Gewinner am US-Aktienmarkt war gestern das Papier von Biogen (WKN: 789617). Grund hierfür waren jedoch nicht in erster Linie die vorgelegten, sehr guten Quartalszahlen, sondern

Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Entpuppt sich Gilead Sciences doch noch als Value Trap?
Entpuppt sich Gilead Sciences doch noch als Value Trap?
Das Biotech-Unternehmen Gilead Sciences (WKN: 885823) habe ich noch gar nicht so lange auf dem Schirm und heute weiß ich, dass ich die Finger ganz davon hätte sein lassen sollen. Vor 15....
Here's How AbbVie Inc. Crushed It in 2017
Here's How AbbVie Inc. Crushed It in 2017
It's been a tremendous year for AbbVie Inc. (NYSE: ABBV) shareholders. Shares of the Abbott spinoff have gained 56.5% this year as investors cheered a handful of important developments. As the....
3 Reasons to Own Pfizer's Stock in 2018
3 Reasons to Own Pfizer's Stock in 2018
Despite losing nearly $30 billion in branded pharma sales due to the loss of exclusivity for key brands like Celebrex, Lipitor, Lyrica, and Viagra over the course of 2011 to 2020, Pfizer (NYSE:....
Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
It's been a great year for most investors, with the S&P 500 index rising close to 20% in 2017. But not every stock has performed that well. The stocks of two S&P 500 members,....
Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY)
Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY)
If AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. Over the summer, AbbVie would have pulled....
If I Could Only Buy 1 Healthcare Stock in January, It Would Be This One
If I Could Only Buy 1 Healthcare Stock in January, It Would Be This One
Pfizer Inc. (NYSE: PFE) is the one healthcare stock I'd add to my portfolio in January. Why? The company's turning the corner back toward growth, its R&D team is delivering important wins, its....
3 Promising Cancer Immunotherapies to Watch in 2018
3 Promising Cancer Immunotherapies to Watch in 2018
Any way you look at it, immunotherapies -- also known as immuno-oncology (I-O) drugs -- are hot commodities. Two of the top three cancer drugs projected to be the biggest winners in the next five....